ALKternate: A Proof of Concept Study in ALK-Rearranged NSCLC Alternating Lorlatinib With Crizotinib After Disease Progression

被引：0
|
作者：
Itchins, M. [1 ]
Liang, S. [1 ]
Brown, C. [2 ]
Solomon, B. [3 ]
Pavlakis, N. [1 ]
机构：
[1] Royal North Shore Hosp, Med Oncol, St Leonards, NSW, Australia
[2] Univ Sydney, Nhmrc Clin Trials Ctr, Camperdown, NSW, Australia
[3] Peter Maccallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
Drug resistance; ALK; Clinical trial;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P47.12
引用
收藏
页码：S1101 / S1102
页数：2
相关论文
共 50 条
  • [11] Lorlatinib in advanced ALK-rearranged NSCLC - real-world experience in a UK population
    Lucas, Tylan
    Hassan, Heba
    Sattar, Alisha
    So, Alfred
    Buckley, Thomas
    Hunter, Sarah
    Masento, Sebastian
    Naureen, Sofia
    Benafif, Sarah
    Boleti, Ekaterina
    Tarver, Kathryn
    Ahmad, Tanya
    Newsom-Davis, Tom
    Janusweski, Adam
    Shah, Riyaz
    Ghosh, Sharmistha
    Hughes, Daniel Johnathan
    LUNG CANCER, 2024, 190
  • [12] Treatment with Alectinib after Crizotinib-Induced Hepatitis in an ALK-Rearranged Advanced NSCLC-Patient
    Duarte, F.
    Rodrigues, L.
    Paes, F.
    Diniz, P.
    De Almada, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S667 - S667
  • [13] Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib
    Muller, Ittai B.
    De Langen, Adrianus J.
    Honeywell, Richard J.
    Giovannetti, Elisa
    Peters, Godefridus J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (02) : 147 - 157
  • [14] ctDNA NGS for Guiding Crizotinib Treatment in ALK-Rearranged Advanced NSCLC Patients (Pts)
    He, Y.
    Zhao, J.
    Liu, C.
    Chen, R.
    Xia, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S573 - S573
  • [15] Clinical Benefit of Continuing Crizotinib Therapy after Initial Disease Progression in Chinese Patients with Advanced ALK -Rearranged NSCLC
    Hong, Xiangchan
    Wu, Haiying
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1174 - S1174
  • [16] Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance
    Russo, Alessandro
    Franchina, Tindara
    Ricciardi, Giuseppina Rosaria Rita
    Ferraro, Giuseppa
    Scimone, Antonino
    Bronte, Giuseppe
    Russo, Antonio
    Rolfo, Christian
    Adamo, Vincenzo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (06) : 615 - 623
  • [17] Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC
    Nagasaka, Misako
    Ou, Sai-Hong Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 532 - 536
  • [18] Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib
    Nishino, Mizuki
    Sacher, Adrian G.
    Gandhi, Leena
    Chen, Zhao
    Akbay, Esra
    Fedorov, Andriy
    Westin, Carl F.
    Hatabu, Hiroto
    Johnson, Bruce E.
    Hammerman, Peter
    Wong, Kwok-kin
    EUROPEAN JOURNAL OF RADIOLOGY, 2017, 88 : 15 - 20
  • [19] Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs
    Leporati, Rita
    Miliziano, Daniela
    Beninato, Teresa
    Mazzeo, Laura
    Manglaviti, Sara
    Brambilla, Marta
    Occhipinti, Mario
    Prelaj, Arsela
    Proto, Claudia
    Lo Russo, Giuseppe
    TUMORI JOURNAL, 2024,
  • [20] Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
    Takeyasu, Yuki
    Yoshida, Tatsuya
    Masuda, Ken
    Matsumoto, Yuji
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Ohe, Yuichiro
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (05):
12345